Trial Profile
A Phase Ib Clinical Study With Extension Phase to Evaluate Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib in the Treatment of Relapsed or Metastatic NSCLC Patients
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Mar 2023
Price :
$35
*
At a glance
- Drugs Fruquintinib (Primary) ; Geptanolimab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Genor Biopharma
- 02 Mar 2021 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified 2 Mar 2021).
- 02 Mar 2021 Planned End Date changed from 1 Dec 2020 to 1 Dec 2022.
- 02 Mar 2021 Planned primary completion date changed from 1 Dec 2020 to 1 Dec 2021.